Table of contents

Papers

• Lipid lowering agents are associated with a slower cognitive decline in Alzheimer’s disease (16 November, 2005)

  I Masse, R Bordet, D Deplanque, A Al Khedr, F Richard, C Libersa, F Pasquier
• Metacognitive deficits in frontotemporal dementia (16 November, 2005)

  P J Eslinger, K Dennis, P Moore, S Antani, R Hauck, M Grossman
• Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial (16 November, 2005)

  W G Ondo, R Fayle, F Atassi, J Jankovic
• Stimulation of the subthalamic nucleus in Parkinson’s disease: a 5 year follow up (16 November, 2005)

  W M M Schüpbach, N Chastan, M L Welter, J L Houeto, V Mesnage, A M Bonnet, V Czernecki, D Maltête, A Hartmann, L Mallet, B Pidoux, D Dormont, S Navarro, P Cornu, A Mallet, Y Agid
• When is Onuf’s nucleus involved in multiple system atrophy? A sphincter electromyography study (16 November, 2005)

  T Yamamoto, R Sakakibara, T Uchiyama, Z Liu, T Ito, Y Awa, K Yamamoto, M Kinou, T Yamanishi, T Hattori
• Influence of pre-existing dementia on the risk of post-stroke epileptic seizures (16 November, 2005)

  C Cordonnier, H Hénon, P Derambure, F Pasquier, D Leys
• Do stroke patients with normal carotid arteries require TEE for exclusion of relevant aortic plaques? (16 November, 2005)

  A Harloff, M Handke, A Geibel, E Oehm, B Guschlbauer, M Olschewski, A Hetzel
• Pathogenesis of deep white matter medullary infarcts: a diffusion weighted magnetic resonance imaging study (16 November, 2005)

  P H Lee, S H Oh, O Y Bang, I S Joo, K Huh
• Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up (16 November, 2005)

  J P Zajicek, H P Sanders, D E Wright, P J Vickery, W M Ingram, S M Reilly, A J Nunn, L J Teare, P J Fox, A J Thompson
• Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients (16 November, 2005)

  P Gallien, J-M Reymann, G Amarenco, B Nicolas, M de Sèze, E Bellissant
• Psychometric evaluation of the multiple sclerosis impact scale (MSIS-29) for proxy use (16 November, 2005) Free

  F A H van der Linden, J J Kragt, M Klein, H M van der Ploeg, C H Polman, B M J Uitdehaag
• The safety of antiepileptic drug withdrawal in patients with non-epileptic seizures (8 June, 2005)

  M Oto, C Espie, A Pelosi, M Selkirk, R Duncan
• [¹¹C]-Methionine PET: dysembryoplastic neuroepithelial tumours compared with other epileptogenic brain neoplasms

  (16 November, 2005)

  D S Rosenberg, G Demarquay, A Jouvet, D Le Bars, N Streichenberger, M Sindou, N Kopp, F Mauguière, P Ryvlin
• Clinical course, pathological correlations, and outcome of biopsy proved inflammatory demyelinating disease (16 November, 2005)

  S J Pittock, R L McClelland, S J Achenbach, F Konig, A Bitsch, W Brück, H Lassmann, J E Parisi, B W Scheithauer, M Rodriguez, B G Weinshenker, C F Lucchinetti
• Peripheral neuropathy in metachromatic leucodystrophy. A study of 40 cases from south India (16 November, 2005)

  P S Bindu, A Mahadevan, A B Taly, R Christopher, N Gayathri, S K Shankar
• Antinuclear antibodies define a subgroup of paraneoplastic neuropathies: clinical and immunological data (16 November, 2005)

  M Tschernatsch, E Stolz, M Strittmatter, M Kaps, F Blaes
• Validation of a short disease specific quality of life scale for hemifacial spasm: correlation with SF-36 (16 November, 2005)

  E K Tan, S Fook-Chong, S-Y Lum, J Thumboo